Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea: Disease State and Treatment Overview

This publication reviews the impact of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea as well as the etiology and assessment of EDS, impact of comorbidities on the disease, and treatment options and guidelines.

Download PDF: Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea: Disease State and Treatment Overview

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Orthopedic surgeon holds bone x-ray | Image Credit: © tippapatt - stock.adobe.com

Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System

ByHannah I. Travers, MD,Mikhail Kuznetsov, MD,John Mazzocco, MD,Nicholas Pagani, MD,Tricia Ide, DNP, RN,Brian L. Hollenbeck, MD,Eric L. Smith, MD

June 3rd 2026

Social Needs Screening and Supplemental Benefits in Medicare Advantage

ByJessica I. Billig, MD, MSc,Michael D. Dang, MS,Jennifer R. Cardin, MSc,Joseph H. Joo, MD, MS,Joshua M. Liao, MD, MSc

Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea: Disease State and Treatment Overview

Related Content

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System

Social Needs Screening and Supplemental Benefits in Medicare Advantage

Trending on AJMC

How Often Do Health Insurers Deny Doctor-Recommended Care?

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

Sudden Death in HFpEF Often Preceded by Clinical Decline

New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor

What Managed Care Should Watch at ADA 2026 Scientific Sessions